Hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-05-06Clinical Trial Update: ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies [Phase 1, Phase 2]
Phase 1/2 trial of acalabrutinib (ACP-196) in combination with pembrolizumab in hematologic malignancies has completed with results posted i…
-
CLINICAL_TRIALS trial_result · 2022-04-12Clinical Trial Update: A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant, [Phase 3]
Phase 3 trial comparing nivolumab plus brentuximab vedotin vs brentuximab vedotin alone in advanced stage classical Hodgkin lymphoma; trial …
-
CLINICAL_TRIALS trial_result · 2022-04-07Clinical Trial Update: Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies [Phase 3]
Phase 3 clinical trial update on stem cell transplantation from partially HLA-m matched related donors for hematologic malignancies; trial c…
-
CLINICAL_TRIALS trial_result · 2022-02-17Clinical Trial Update: An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma [Phase 1, Phase 2]
This clinical trial update reports on the safety and effectiveness of combining Nivolumab and Daratumumab in patients with multiple myeloma …
-
CLINICAL_TRIALS trial_result · 2022-02-17Clinical Trial Update: Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating Brentuximab Vedotin + DHAP in relapsed or refractory classical Hodgkin lymphoma.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-02-17Clinical Trial Update: A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma [Phase 3]
Phase III clinical trial update for Penpulimab in relapsed and refractory classical Hodgkin's lymphoma (NCT05244642).
-
CLINICAL_TRIALS trial_result · 2022-02-15Clinical Trial Update: T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma [Phase 1]
Phase 1 trial evaluating T cells engineered with fully-human anti-CD19 and anti-CD20 CARs for B-cell malignancies and Hodgkin lymphoma; the …
-
CLINICAL_TRIALS trial_result · 2022-02-08Clinical Trial Update: Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma [Phase 2]
A Phase 2 trial evaluating Brentuximab Vedotin (Adcetris) in combination with chemotherapy and radiation for younger patients with Stage IIB…
-
CLINICAL_TRIALS trial_result · 2021-12-17Clinical Trial Update: PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating PD-1 inhibitor with decitabine followed by autologous stem cell transplant as second-line therapy for relapsed or r…
-
CLINICAL_TRIALS trial_result · 2021-12-07Clinical Trial Update: Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE [Phase 1, Phase 2]
Phase 1/2 trial evaluating brentuximab vedotin in refractory/relapsed Hodgkin lymphoma treated with ICE; study completed.
-
CLINICAL_TRIALS trial_result · 2021-11-19Clinical Trial Update: Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating gemcitabine and bendamustine in relapsed or refractory Hodgkin lymphoma; completed with results posted i…
-
CLINICAL_TRIALS trial_result · 2021-08-25Clinical Trial Update: 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial updating the safety and preliminary efficacy of 10-Propargyl-10-Deazaaminopterin in recurrent or refractory lymphoma (non-Ho…
-
CLINICAL_TRIALS trial_result · 2021-08-19Clinical Trial Update: R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma [Phase 3]
Phase 3 trial comparing R-ABVD to ABVD-RT in early-stage Hodgkin lymphoma; study terminated.
-
CLINICAL_TRIALS trial_result · 2021-07-26Clinical Trial Update: Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD [Phase 2]
Phase 2 trial updates consolidation Brentuximab Vedotin in stage I/II Hodgkin lymphoma with PET positivity after 2 cycles of ABVD.
-
CLINICAL_TRIALS trial_result · 2021-07-16Clinical Trial Update: Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating carfilzomib and TGR-1202 in relapsed/refractory lymphoma and Hodgkin disease, terminated with results …
-
CLINICAL_TRIALS trial_result · 2021-07-13Clinical Trial Update: Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial update for ADCT-301 in relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-07-12Clinical Trial Update: A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) [Phase 1]
Phase 1 trial evaluating pembrolizumab (MK-3475) in blood cancers has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-06-24Clinical Trial Update: CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma [Phase 2]
Phase 2 trial evaluating CD8+ memory T-cells as consolidative therapy after donor non-myeloablative hematopoietic cell transplant in leukemi…
-
CLINICAL_TRIALS trial_result · 2021-06-14Clinical Trial Update: Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating chemotherapy guided by PET scan for treatment of Stage I/II Hodgkin lymphoma; results completed with posted results…
-
CLINICAL_TRIALS trial_result · 2021-06-11Clinical Trial Update: Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation [Phase 2]
Phase 2 trial update on Total Body Irradiation with or without Total Lymphoid Irradiation and Anti-Thymocyte Globulin in non-myeloablative h…
-
CLINICAL_TRIALS trial_result · 2021-06-09Clinical Trial Update: Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 study results for a combination regimen of Brentuximab Vedotin with Ifosfamide, Carboplatin, and Etoposide in relapsed or refracto…
-
CLINICAL_TRIALS trial_result · 2021-06-08Clinical Trial Update: Unrelated Umbilical Cord Blood (UBC)Transplantation [NA]
Clinical trial update for unrelated umbilical cord blood transplantation; the study is completed with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-06-01Clinical Trial Update: A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma [Phase 1, Phase 2]
This clinical trial update reports on a pediatric Phase 1/2 study of Brentuximab Vedotin combined with doxorubicin, vinblastine, and dacarba…
-
CLINICAL_TRIALS trial_result · 2021-04-19Clinical Trial Update: Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating ITF2357 (histone deacetylase inhibitor) followed by mechlorethamine in relapsed/refractory Hodgkin's lymphoma; st…
-
CLINICAL_TRIALS trial_result · 2021-04-13Clinical Trial Update: A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT [Phase 2]
Phase II, multi-center, non-randomized open-label study evaluating tislelizumab with AVD regimen for newly diagnosed advanced Hodgkin lympho…